Background The Multiple Sclerosis Walking Scale (MSWS-12) is the predominant patient-reported measure of multiple sclerosis (MS) -elated walking ability, yet it had not been analyzed using item ...

The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.

The drug fampridine improves walking ability in some patients with multiple sclerosis (MS) and seems to be well-tolerated in patients with all disease course types of MS. The results of this Phase III ...

Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis. People with MS often experience fatigue, with ...

EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful ...